Late-Breaking Clinical Trials

Updated:Aug 25,2015
Scientific Sessions 2015 - November 7-11, 2015

Become a Member

Join or renew your AHA/ASA Professional Membership today to save on registration for all AHA Scientific Sessions.

Late Breaking Clinical Trial Submission is closed.

Registration Information

Registration is now open!

Register Online and Save $20

Late-Breaking Clinical Trials

Late-Breaking Clinical Trials sessions are innovative, provide the latest breakthroughs in clinical science and potentially will have a significant impact on clinical practice. Clinical Science Report sessions will highlight trial updates, registries and important clinical science.

Here are highlights of the recently selected 2015 Late-Breaking Clinical Trials. Complete details will be available soon.  

Heart Failure

FIGHT: GLP-1 Receptor Agonist in HFpEF
Outcome of GLP-1 receptor agonist treatment on clinical status at 180 days for high-risk HFpEF patients.
NEAT HFpEF: Nitrates and Activity in HFpEF
Ability of nitrates to improve activity tolerance in ambulatory HFpEF patients.
SOCRATES/ REDUCED: Vericiguat Use in Chronic HF
Safety and effectiveness of vericiguat to reduce NT-ProBNP and improve echocardiographic measurements and QOL in worsening chronic HF.
BEAT HF: Telemonitoring After Discharge
Effectiveness of incorporating the care transition approach with telemonitoring on remote patient management after hospital discharge.  


ROC-CCC: Continuous vs Interrupted Chest Compressions in CPR
Outcomes of continuous versus interrupted chest compressions in out of hospital arrest.
PROACT 4: Point-of-Care Troponin Testing and Time-to-Diagnosis for Acute CV Symptoms
Point-of-care troponin testing and time-to-diagnosis for acute CV symptoms to provide rapid out-of-hospital acute CV treatment.


EVITA: Varenicline Use in Smoking Cessation
Determined the safety and efficacy of varenicline, when started in the hospital after ACS, in smoking cessation.
50/50: Peer Group Intervention in Risk Factor Modification
Peer-group intervention on improving CV risk factors such as tobacco, other substance abuse, eating disorders and chronic illnesses.
MBC2: Genetic Risk Score Knowledge in Cholesterol Lowering
Does knowledge of a genetic risk score for coronary heart disease result in lower low-density lipoprotein cholesterol?
EMPA-REG OUTCOME: Empagliflozin Use in Patients with Type 2 DM
Safety and effectiveness of blood-glucose lowering by pharmacological inhibition of the sodium glucose co-transporter 2 in lowering CVD risk in high-risk patients with type 2 diabetes.


RIVER-PCI: Ranolazine Use for Incomplete Revascularization
Effectiveness of ranolazine in reducing post-PCI angina and ischemic events in the long-term management of patients with incomplete revascularization.
IVUS XPL: Everolimus-Eluting Stents in Long Coronary Lesions
Intravascular Ultrasound-Guided Everolimus-Eluting Stents Implantation in long coronary lesions—clinical outcomes.
PEGASUS-TIMI 54: Long-Term Ticagrelor Efficacy and Compliance
Efficacy of long-term ticagrelor compliance; why stable, prior MI patients discontinue it.
DAPT Study Analysis: Individualizing DAPT After PCI
Individualization of the duration of dual antiplatelet therapy after PCI.

Novel Therapies (First in Man)

AUGMENT HF: Advanced HF Treatment with Algisyl at 1 year
1-Year Efficacy Follow-up: LV augmentation with Algisyl-LVR in moderate to advanced HF treatment.
BEAT-HF (B3): Efficacy of an Oral β3-Adrenoceptor Agonist in Chronic HF
First-in-man randomized trial of an oral β3-adrenoceptor agonist in chronic heart failure.
PRADA: Preventing Cardiac Dysfunction During Breast Cancer Therapy
Primary results of a RCT for the prevention of cardiac dysfunction during adjuvant breast cancer therapy.
ANNEXA-R: Sustained Reversal of Rivaroxaban Anticoagulation in Elderly by Andexanet Alfa
A phase 3 RCT demonstrating sustained reversal of Rivaroxaban-induced anticoagulation in older subjects by Andexanet Alfa, a universal antidote for Factor XA Inhibitors.
Preventing Renal Injury with Nitric Oxide During CPB
Nitric Oxide and preventing acute kidney injury during and after prolonged cardiopulmonary bypass.
RWISE: Ranolazine and Microvascular Coronary Dysfunction
Effectiveness of ranolazine in reducing angina in patients with microvascular coronary dysfunction. 


ENDOCARDITIS: Infective Endocarditis After 2009 ESC Guideline
Evaluation of the incidence of infective endocarditis following the 2009 ESC Guideline Update.
SHARE-HCM: Sarcomere Mutations and Clinical Severity
Analysis of sarcomere mutations and their relationships to severity of clinical profile in genotyped HCM patients.
CANOA: Clopidogrel and Aspirin for Migraine After Transcatheter ASD Closure
Effectiveness of clopidogrel in addition to aspirin for preventing new-onset migraine attacks subsequent to transcatheter atrial septal defect closure.
EWOLUTION: LA Appendage Occlusion and Stroke with WATCHMAN Device
Left Atrial Appendage Occlusion effectiveness and non-inferiority compared to oral anticoagulation in AF patients related to procedural success and complications as a stroke reduction strategy with the WATCHMAN device.


Medicare ICD Registry Analysis: Wide QRS, RBBB and CRT
Medicare ICD Registry Analysis of Cardiac Resynchronization Therapy in patients with Wide QRS and Right Bundle Branch Block.
Micra Transcatheter Pacing Study: Miniaturized, Leadless, Transcatheter-Delivered Cardiac Pacing
Miniaturized, leadless, transcatheter-delivered cardiac pacing.
Video Decision Support Tool for Patients with Advanced HF
Video decision support tool to depict goals of care and resuscitation options for patients with advanced HF.


JUPITER: Variability in LDL Cholesterol Response to Statin
Individual variability in LDL cholesterol response to statin therapy and the relationship of on-treatment lipid level magnitude with event reduction.
CAN HEART: HDL Cholesterol and Mortality
Importance of HDL cholesterol in predicting CV and non-cardiovascular mortality in 630,000 persons without prior CVD.
ACCORDIAN BP:  Long-Term CV Effects of 4.9 Years of Intensive BP Control in Type 2 DM
Long-term CV effects of 4.9 years of intensive blood pressure control in Type 2 Diabetes Mellitus.
REVASC DM:  Benefits of CABG vs. PCI in Diabetic Patients via Registries and Cohort Studies
Benefits of CABG vs. PCI in diabetic patients from clinical registries or cohort studies.

Submission Guidelines